Monitoring of High-Risk Areas: Cancer Wards

  • Jeewan Garg
  • Anupam Sachdeva


Infection continues to be the foremost cause of morbidity and mortality in patients undergoing antineoplastic chemotherapy. Despite improved diagnostic tools, better understanding of infectious etiologies, and the advent of several new antimicrobials, infections continue to be a major problem [1]. Cancer patients suffer from host immune system defects and anatomic barrier disruption that predispose them to infections. Understanding the different risk factors in the individual patient is necessary to implement the appropriate preventive strategies.


Antimicrobial Prophylaxis Undergo Bone Marrow Transplant Invasive Candidal Infection Infection Control Team Antineoplastic Chemotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Bodey GP. Managing infections in the immunocompromised patient. Clin Infect Dis. 2005;40 Suppl 4:S239.PubMedCrossRefGoogle Scholar
  2. 2.
    Gea-Banacloche JC, Palmore T, Walsh TJ, Holland SM, Segal BH. Infections in the cancer patient. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. Principles & practice of oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 2569–616.Google Scholar
  3. 3.
    Young JH, Weisdorf DJ. Clinical approach to infections in the compromised host. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Silberstein LE, McGlave P, et al., editors. Hematology: basic principles and practice. 5th ed. Philadelphia: Churchill Livingstone Elsevier; 2009. p. 1243–88.Google Scholar
  4. 4.
    Larson EL. APIC guideline for hand washing and hand antisepsis in health care settings. Am J Infect Control. 1995;23:251–69.PubMedCrossRefGoogle Scholar
  5. 5.
    Vusirikala M. Supportive care in hematologic malignancies. In: Greer JP, Foerster J, Rodgers GM, Paraskevas F, Glader B, Arber DA, et al., editors. Wintrobe’s clinical hematology. 12th ed. Philadelphia: Lippincott Williams & Wilkins; 2009. p. 1747–90.Google Scholar
  6. 6.
    DeMille D, Deming P, Lupinacci P, et al. The effect of the neutropenic diet in the outpatient setting: a pilot study. Oncol Nurs Forum. 2006;33:337–43.PubMedCrossRefGoogle Scholar
  7. 7.
    Wilson BJ. Dietary recommendations for neutropenic patients. Semin Oncol Nurs. 2002;18:44–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Hahn T, Cummings KM, Michalek AM, et al. Efficacy of high-efficiency particulate air filtration in preventing aspergillosis in immunocompromised patients with hematologic malignancies. Infect Control Hosp Epidemiol. 2002;23:525–31.PubMedCrossRefGoogle Scholar
  9. 9.
    Hughes WT, Rivera GK, Schell MJ, et al. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1987;316:1627–32.PubMedCrossRefGoogle Scholar
  10. 10.
    De Pauw BE, Novakova IR, Ubachs E, et al. Co-trimoxazole in patients with haematological malignancies: a review of 10-years’ clinical experience. Curr Med Res Opin. 1988;11:64–72.PubMedCrossRefGoogle Scholar
  11. 11.
    Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol. 1998;16:1179–87.PubMedGoogle Scholar
  12. 12.
    Imran H, Tlvejeh IM, Arndt CA, et al. Fluoroquinolone prophylaxis in patients with neutropenia: a meta-analysis of randomized placebo-controlled trials. Eur J Clin Microbiol Infect Dis. 2008;27:53–63.PubMedCrossRefGoogle Scholar
  13. 13.
    Bow EJ, Laverdiere M, Lussier N, et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer. 2002;94:3230–46.PubMedCrossRefGoogle Scholar
  14. 14.
    Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized, placebo-controlled, double-blind, multicenter trial. Ann Intern Med. 1993;118:495–503.PubMedCrossRefGoogle Scholar
  15. 15.
    Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol. 2007;25:5471–89.PubMedCrossRefGoogle Scholar
  16. 16.
    Saral R, Ambinder RF, Burns WH, et al. Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. Ann Intern Med. 1983;99:773–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Selby PJ, Powles RL, Easton D, et al. The prophylactic role of intravenous and long term oral acyclovir after allogeneic bone marrow transplantation. Br J Cancer. 1989;59:434–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer India 2014

Authors and Affiliations

  1. 1.Department of HematologySir Ganga Ram HospitalNew DelhiIndia
  2. 2.Institute of Child HealthSir Ganga Ram HospitalNew DelhiIndia

Personalised recommendations